Results 201 to 210 of about 124,209 (305)

Intraocular Tumors in Horses: Diagnosis, Tumor Classification, Oncologic Assessment and Therapy. [PDF]

Vet Sci
Ostendarp C, Barton AK.
europepmc   +1 more source

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers

British Journal of Clinical Pharmacology, EarlyView.
Aim Fluorescence‐guided surgery enhances intraoperative visualization of anatomical structures. Nizaracianine is a near‐infrared fluorescent agent that is exclusively renally cleared in animal models. It enables real‐time ureteral imaging and identification, potentially reduces risk of injury and facilitates assessment before surgical closure.
Lisanne K. A. Neijenhuis, Cedric M. W. Pesch, John V. Frangioni, Alexander L. Vahrmeijer, Jacobus Burggraaf, Naomi B. Klarenbeek   +5 more
wiley   +1 more source

Linked color imaging versus artificial intelligence-assisted linked color imaging for neoplasia detection in the colorectum: a randomized trial in Brazil. [PDF]

Clin Endosc
Santos CEOD, Yoshida N, Tchekmedyian AJ, Santos GMD, Costa LA, Sanmartin IDA, Pereira-Lima J.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Intraocular Metastasis: Differential Diagnosis and Management. [PDF]

Clin Exp Ophthalmol
Μachairoudia G, Kazantzis D, Negretti GS, Sagoo MS.   +3 more
europepmc   +1 more source

Computed tomographic appearance of melanomas in the equine head: 13 cases [PDF]

A, Albanese, Barnett, Chénier, Cissell, Cotchin, Crijns, Dakin, Dixon, Dyson, Enochs, Fintl, Fukunaga, Ginaldi, Grahn, Holtås, Kalkman, Kato, Lerner, Lucas, Manso-Díaz, McFadyean, Moore, Parizel, Pellegrini, Phillips, Premkumar, Sasaki, Seltenhammer, Textor, Tietje, Tremaine, Uozumi, Valentine, WG, Wörz   +35 more
core   +1 more source

[Glucose tolerance in patients with eye neoplasms].

Klinika oczna, 1971
S, Mondelski, Z, Kierzkowski
openaire   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source